Login to Your Account



'Buy American'

Daiichi Sankyo Bolsters Pipe with $935M Plexxikon Buy

By Tom Wall


Wednesday, March 2, 2011
In the latest acquisition of a U.S. biotech with promising oncology offerings by a Japanese company, Daiichi Sankyo Co. Ltd., of Tokyo, bought Plexxikon Inc., of Berkeley, Calif., and its promising melanoma drug PLX4032, for $805 million up front and near-term milestones of $130 million linked to approval of PLX4032.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription